Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

Future Microbiol. 2008;3(6):649-660.

The FDA announced the approval of a new treatment for pneumonia caused by certain difficult-to-treat bacteria, offering hope ...

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Biofilms are complex, three-dimensional structures ... often multi-drug resistant pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Staphylococcus aureus, and Enterococcus faecalis.

Testing new antibiotics in India, South Africa, or Brazil, where they are needed most, makes scientific sense. But it’s not without challenges. If the drugs lack global viability, they are less likely ...

药品说明书是临床医师开立药物的主要依据。但随着循证医学的日益发展，药物临床试验周期长，药品说明书更新慢等问题使许多药品说明书中的使用适应证、用量及用法远远落后于临床实际应用。药物治疗是抢救重症患者必不可少的重要治疗手段。而重症患者是一个特殊群体，疾病谱涉及多个学科，病情危重复杂，常合并多器官功能损害 ...

Antibiotics are very complex. Unlike vaccines ... Two pathogens of particular concern are Acinetobacter baumannii and Enterobacter species. "Those two pathogens are concerning from a Latin ...